Vyant Bio (VYNT) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 01, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	CANCER GENETICS, INC
Trading Symbol	CGIX
Entity Central Index Key	1,349,929
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		10,651,924

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 19,917,926	$ 25,554,064
Accounts receivable, net of allowance for doubtful accounts	5,165,093	5,028,620
Other current assets	1,540,501	1,172,750
Other current assets	26,623,520	31,755,434
Total current assets	3,778,605	4,310,126
FIXED ASSETS, net of accumulated depreciation
Restricted cash	300,000	6,300,000
Patents	585,259	502,767
Investment in joint venture	300,225	1,047,744
Goodwill	3,187,495	3,187,495
Deposit for acquisition	880,000	0
Other	324,641	1,564
Total other assets	5,577,620	11,039,570
Total Assets	35,979,745	47,105,130
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable and accrued expenses	4,437,373	3,762,567
Obligations under capital leases, current portion	61,079	58,950
Deferred revenue	1,173,128	544,446
Bank term note, current portion	833,333	0
Total current liabilities	6,504,913	4,365,963
Obligations under capital leases	254,021	300,385
Deferred rent payable and other	289,319	347,840
Line of credit	0	6,000,000
Warrant liability	34,000	52,000
Acquisition note payable	657,744	560,341
Deferred revenue, long-term	782,818	924,850
Bank term note	5,138,783	0
Total liabilities	13,661,598	12,551,379
STOCKHOLDERS’ EQUITY
Preferred stock, authorized 9,764,000 shares, $0.0001 par value, none issued	0	0
Common stock, authorized 100,000,000 shares, $0.0001 par value, 9,861,340 and 9,821,169 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	986	982
Additional paid-in capital	114,754,824	112,520,268
Accumulated (deficit)	(92,437,663)	(77,967,499)
Total Stockholders’ Equity	22,318,147	34,553,751
Total Liabilities and Stockholders’ Equity	$ 35,979,745	$ 47,105,130

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	9,764,000	9,764,000
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares issued (in shares)	0	0
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	9,861,340	9,821,169
Common stock, shares outstanding (in shares)	9,861,340	9,821,169

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenue	$ 4,000,332	$ 3,221,850	$ 12,555,806	$ 6,163,895
Cost of revenues	3,103,227	2,565,715	9,342,399	5,358,872
Gross profit	897,105	656,135	3,213,407	805,023
Operating expenses:
Research and development	1,801,813	1,390,189	4,335,235	3,092,733
General and administrative	3,487,242	3,104,100	9,535,723	8,230,966
Sales and marketing	1,242,803	1,070,531	3,543,047	2,737,967
Total operating expenses	6,531,858	5,564,820	17,414,005	14,061,666
Loss from operations	(5,634,753)	(4,908,685)	(14,200,598)	(13,256,643)
Other income (expense):
Interest expense	(111,620)	(36,166)	(227,140)	(408,087)
Interest income	4,906	18,789	30,288	57,130
Change in fair value of acquisition note payable	315,453	0	(90,714)	0
Change in fair value of warrant liability	214,000	129,000	18,000	324,000
Total other (expense)	422,739	111,623	(269,566)	(26,957)
Loss before income taxes	(5,212,014)	(4,797,062)	(14,470,164)	(13,283,600)
Income tax provision (benefit)	0	0	0	(1,813,941)
Net (loss)	$ (5,212,014)	$ (4,797,062)	$ (14,470,164)	$ (11,469,659)
Basic net (loss) per share (usd per share)	$ (0.54)	$ (0.50)	$ (1.49)	$ (1.22)
Diluted net (loss) per share (usd per share)	$ (0.56)	$ (0.51)	$ (1.49)	$ (1.25)
Basic Weighted-Average Shares Outstanding (in shares)	9,726,067	9,575,789	9,714,824	9,386,613
Diluted Weighted-Average Shares Outstanding (in shares)	9,727,597	9,575,789	9,716,214	9,403,245

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	$ (14,470,164)	$ (11,469,659)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Depreciation	971,192	487,656
Amortization	26,177	20,146
Provision for bad debts	212,914	0
Equity-based consulting and compensation expenses	2,177,554	2,129,880
Change in fair value of business acquisition	90,714	0
Change in fair value of warrant liability	(18,000)	(324,000)
Amortization of loan guarantee fees, financing fees and debt issuance costs	4,960	310,500
Loss in equity method investment	747,519	659,426
Changes in:
Accounts receivable	(349,387)	(521,429)
Other current assets	(367,751)	(169,940)
Other non-current assets	(85,856)	0
Accounts payable, accrued expenses and deferred revenue	1,330,145	985,644
Deferred rent and other	(58,521)	(18,050)
Net cash (used in) operating activities	(9,950,504)	(7,909,826)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	(439,671)	(944,423)
Decrease (increase) in restricted cash	6,000,000	(6,000,000)
Patent costs	(108,669)	(95,408)
Investment in JV	0	(1,000,000)
Deposit for acquisition of Response Genetics	(880,000)	0
Cash used in acquisition of Gentris, net of cash received	0	(3,180,930)
Cash from acquisition of BioServe	0	311,264
Net cash provided by (used in) investing activities	4,571,660	(10,909,497)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on capital lease obligations	(44,235)	(21,554)
Payments for deferred equity offering costs	(237,221)	0
Proceeds from warrant exercises	0	178,102
Proceeds from option exercises	23,480	79,018
Proceeds from offering of common stock, net of offering costs	33,526	0
Principal payments on notes payable	0	(127,532)
Payment of debt issuance costs	(32,844)	0
Net cash provided by (used in) financing activities	(257,294)	108,034
Net (decrease) in cash and cash equivalents	(5,636,138)	(18,711,289)
CASH AND CASH EQUIVALENTS
Beginning	25,554,064	49,459,564
Ending	19,917,926	30,748,275
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	157,603	92,692
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangements	0	40,922
Cashless exercise of derivative warrants	0	125,000
Value of shares issued as partial consideration of Gentris and BioServe	0	1,515,992
Net tangible assets acquired via acquisition	0	1,255,084
BioServe [Member]
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Change in fair value of business acquisition	90,714	0
Gentris [Member]
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Change in fair value of business acquisition	$ (162,000)	$ 0

Organization, Description of Bu

Organization, Description of Business, Basis of Presentation and Acquisition	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Description of Business, Basis of Presentation and Acquisition	Organization, Description of Business, Basis of Presentation and Acquisitions We are an oncology diagnostics company focused on developing, commercializing and providing DNA-based tests and services to improve the personalization of cancer treatment and to better inform biopharmaceutical companies of genomic factors influencing subject responses to therapeutics. Our vision is to become the oncology diagnostics partner for companies and clinicians by participating in the entire care continuum from bench to bedside. We believe the diagnostic industry is undergoing a metamorphosis in its approach to oncology testing, embracing individualized medicine as a means to drive higher standards of patient treatment and disease management. Similarly, biopharmaceutical companies are increasingly engaging companies such as ours to provide information on clinical trial participants’ DNA profiles in order to identify genomic variations that may be responsible for differing responses to pharmaceuticals, and particularly to oncology drugs, thereby increasing the efficiency of trials while lowering related costs. We believe tailored therapeutics can revolutionize oncology medicine through DNA-based testing services, enabling physicians and researchers to target the factors that make each patient and disease unique. We have created a unique position in the industry by providing targeted somatic analysis of tumor sample cells alongside germline analysis of an individual’s non-cancerous cells’ DNA as we attempt to reach the next milestone in personalized medicine. We were incorporated in the State of Delaware on April 8, 1999 and have offices and state-of-the-art laboratories located in New Jersey, North Carolina, Shanghai (China), and Hyderabad (India). Our laboratories comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, NY State and NABL (India).We have two advisory boards to counsel our scientific and clinical direction. Our Scientific Advisory Board is comprised of preeminent scientists and physicians from the fields of cancer biology, cancer pathology, cancer medicine and molecular genetics. Our Clinical Advisory Board is comprised of clinicians and scientists focused on clinical implementation of our proprietary tests and services and mapping those tests and services to patient needs. Our services are built on a foundation of world-class scientific knowledge and intellectual property in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers such as Memorial Sloan-Kettering, Mayo Clinic, and the National Cancer Institute. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 16, 2015. The consolidated balance sheet as of December 31, 2014, included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2015. In the second quarter of 2015, we adopted ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. Previously, debt issuance costs were recorded as assets on the balance sheet. This update requires that debt issuance costs related to a debt liability be presented on the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. This update does not change the recognition and measurement of debt issuance costs and requires retrospective adoption. We did not have debt issuance costs in the December 31, 2014 Consolidated Balance Sheet. 2014 Acquisitions On July 16, 2014, we purchased substantially all of the assets of Gentris Corporation, (“Gentris”), with its principal place of business in North Carolina, for approximately $4.8 million . There were no changes in the preliminary purchase price allocation or goodwill impairment for Gentris during the nine months ended September 30, 2015 . On August 18, 2014, we acquired BioServe Biotechnologies (India) Private Limited, an Indian corporation (“BioServe”) for an aggregate purchase price of approximately $1.1 million . During the nine months ended September 30, 2015 , there was no goodwill impairment for BioServe, and the preliminary allocation of the purchase price was retrospectively adjusted for a measurement period adjustment to increase goodwill by approximately $193,000 , reduce fixed assets by approximately $136,000 , reduce other assets by approximately $38,000 and reduce other current assets by approximately $19,000 . The fair value of the assets acquired and liabilities assumed as of August 18, 2014 are now as follows: Amount Accounts receivable $ 151,002 Other current assets 102,064 Fixed assets 488,481 Other assets 378,440 Goodwill 734,925 Current liabilities (758,614 ) Other liabilities (22,049 ) Total Purchase Price $ 1,074,249 The results of operations for the three and nine months ended September 30, 2015 include the operations of Gentris and BioServe and include combined revenues of $1,728,238 and $5,357,382 , respectively, and a combined net loss of $1,043,224 and $2,202,254 , respectively. The following table provides certain pro forma financial information for the Company as if the acquisitions of Gentris and BioServe discussed above occurred on January 1, 2014: Three Months Ended Nine Months Ended September 30, 2014 September 30, 2014 Revenue $ 3,493,345 $ 10,329,910 Net loss (6,039,858 ) (13,325,068 ) Basic net loss per share $ (0.63 ) $ (1.40 ) Diluted net loss per share (0.64 ) (1.43 ) Acquisition of Response Genetics, Inc. On October 9, 2015, we acquired substantially all the assets and assumed certain liabilities of Response Genetics, Inc. (“Response Genetics”), with its principal place of business in California, in a transaction valued at approximately $13.4 million , comprised of $7 million in cash and 788,584 shares of the Company’s common stock, with the common stock being valued at $6.4 million . Response Genetics is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. Its mission is to provide personalized genetic information that will help guide physicians and patients in choosing the treatment from which a given patient is most likely to benefit as well as providing clinical testing services for pharmaceutical companies. Response Genetics generated revenues primarily from sales of its ResponseDX® diagnostic tests, which Response Genetics launched in 2008, and by providing clinical trial testing services to pharmaceutical companies. The transaction is being accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed. Accordingly, the allocation of the consideration transferred is preliminary and will be adjusted upon completion of the final valuation of the assets acquired and liabilities assumed. The final valuation is expected to be completed as soon as practicable but no later than 12 months after the closing date of the acquisition. The consolidated financial statements for the three and nine months ended September 30, 2015 and 2014 do not include the operations of Response Genetics. The results of operations for Response Genetics will be included in the Company’s consolidated financial statements beginning on October 9, 2015. The preliminary allocation of the purchase price of the fair value of the assets acquired and liabilities assumed as of October 9, 2015 are as follows: Amount Accounts receivable $ 350,000 Prepaid expenses and other current assets 500,000 Property and equipment 1,000,000 Intangible assets 550,000 Goodwill 11,550,000 Accrued expenses (425,000 ) Obligations under capital leases (125,000 ) Total Purchase Price $ 13,400,000 The following table provides certain pro forma financial information for the Company as if the acquisition of Response Genetics discussed above occurred on January 1, 2014: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Revenue $ 6,879,587 $ 7,686,841 $ 23,043,458 $ 18,805,055 Net loss (10,353,822 ) (8,181,903 ) (27,522,585 ) (21,450,482 ) Basic net loss per share $ (0.98 ) $ (0.79 ) $ (2.62 ) $ (2.11 ) Diluted net loss per share (1.00 ) (0.80 ) (2.62 ) (2.14 ) The pro forma numbers above are derived from historical numbers of the Company and Response Genetics. Over time the operations of Response Genetics will be integrated into the operations of the Company. This integration may change how certain tests are coded and submitted to payers (including Medicare) and, consequently, may result in differences in the future in which revenues and bad debt expenses are recorded when compared with the historical methods of Response Genetics. At the current time, we do not have enough information to prepare a reliable estimate of any possible changes.

Revenue and Accounts Receivable

Revenue and Accounts Receivable	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Revenue and Accounts Receivable	Revenue and Accounts Receivable Revenue by service type for the three and nine months ended September 30, 2015 and 2014 is comprised of the following: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Biopharma Services $ 2,608,427 $ 1,930,799 8,614,441 $ 2,830,687 Clinical Services 1,149,241 1,237,831 3,273,585 3,279,988 Discovery Services 242,664 53,220 667,780 53,220 $ 4,000,332 $ 3,221,850 $ 12,555,806 $ 6,163,895 Accounts receivable by service type at September 30, 2015 and December 31, 2014 consists of the following: September 30, December 31, Biopharma Services $ 2,879,064 $ 3,203,335 Clinical Services 2,401,775 1,925,176 Discovery Services 348,344 151,285 Allowance for doubtful accounts (464,090 ) (251,176 ) $ 5,165,093 $ 5,028,620 Allowance for Doubtful Accounts Balance, December 31, 2014 $ 251,176 Bad debt provision 212,914 Balance, September 30, 2015 $ 464,090 Biopharma Services provide companies customized solutions for patient stratification and treatment selection through an extensive suite of DNA-based testing services. Clinical Services provide information on diagnosis, prognosis and theranosis of cancers to guide patient management. These tests can be billed to Medicare, another third party insurer or the referring community hospital or other healthcare facility. Discovery Services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease. We have historically derived a significant portion of our revenue from a limited number of test ordering sites. Test ordering sites account for all of our Clinical Services revenue along with a portion of our Biopharma Services revenue. Our test ordering sites are hospitals, cancer centers, reference laboratories, physician offices and biopharmaceutical companies. The top five test ordering sites during the three months ended September 30, 2015 and 2014 accounted for 59% and 59% respectively, of our testing volumes, with 27% and 45% , respectively, of the volume coming from community hospitals. During the three months ended September 30, 2015 , there were two biopharmaceutical companies which accounted for approximately 15% and 11% of our total revenue. During the three months ended September 30, 2014 , there were two biopharmaceutical companies which accounted for approximately 17% and 12% of our total revenue, respectively. The top five test ordering sites during the nine months ended September 30, 2015 and 2014 accounted for 80% and 58% respectively, of our testing volumes, with 31% and 40% , respectively, of the volume coming from community hospitals. During the nine months ended September 30, 2015 , there were two biopharmaceutical companies which accounted for approximately 23% and 11% of our total revenue, respectively. During the nine months ended September 30, 2014 , there was one biopharmaceutical company which accounted for approximately 22% of our total revenue. While we have agreements with our Biopharma clients, volumes from these clients are subject to the progression and continuation of the trials which can impact testing volume. We generally do not have formal written agreements with other testing sites and, as a result, we may lose these significant test ordering sites at any time. The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 12% 9% 8% 13% Other insurers 7% 14% 7% 21% Other healthcare facilities 9% 15% 8% 19% 28% 38% 23% 53%

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Earnings Per Share	Earnings Per Share For purposes of this calculation, stock warrants, outstanding stock options and unvested restricted shares are considered common stock equivalents using the treasury stock method, and are the only such equivalents outstanding. Basic net loss and diluted net loss per share data were computed as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net (loss) for basic earnings per share $ (5,212,014 ) $ (4,797,062 ) $ (14,470,164 ) $ (11,469,659 ) Change in fair value of warrant liability 214,000 129,000 18,000 324,000 Net (loss) for diluted earnings per share $ (5,426,014 ) $ (4,926,062 ) $ (14,488,164 ) $ (11,793,659 ) Denominator: Weighted-average basic common shares outstanding 9,726,067 9,575,789 9,714,824 9,386,613 Assumed conversion of dilutive securities: Common stock purchase warrants 1,530 — 1,390 16,632 Potentially dilutive common shares 1,530 — 1,390 16,632 Denominator for diluted earnings per share – adjusted weighted-average shares 9,727,597 9,575,789 9,716,214 9,403,245 Basic net (loss) per share $ (0.54 ) $ (0.50 ) $ (1.49 ) $ (1.22 ) Diluted net (loss) per share $ (0.56 ) $ (0.51 ) $ (1.49 ) $ (1.25 ) The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Common stock purchase warrants 1,041,725 1,531,696 1,041,725 1,531,696 Stock options 2,008,466 1,461,724 2,008,466 1,461,724 Restricted shares of common stock 132,167 105,833 132,167 105,833 3,182,358 3,099,253 3,182,358 3,099,253

Bank Term Note and Line of Cred

Bank Term Note and Line of Credit	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Bank Term Note and Line of Credit	Bank Term Note and Line of Credit On May 7, 2015, we entered into a new debt financing facility with Silicon Valley Bank (“SVB”) to refinance the Company’s cash collateralized loan from Wells Fargo and to provide an additional working capital line of credit. The SVB credit facility provides for a $6.0 million term note (“Term Note”) and a revolving line of credit (“Line of Credit”) for an amount not to exceed the lesser of (i) $4.0 million or (ii) an amount equal to 80% of eligible accounts receivable. The Term Note requires interest-only payments through April 30, 2016 and beginning May 1, 2016, monthly principal payments of approximately $167,000 will be required plus interest through maturity on April 1, 2019 . The interest rate of the Term Note is the Wall Street Journal prime rate plus 2% , with a floor of 5.25% and an additional deferred interest payment of $180,000 will be due upon maturity. The Line of Credit requires monthly interest-only payments of the Wall Street Journal prime rate plus 1.5% and matures on May 7, 2017 . The new loan agreement requires maintenance of certain financial ratios and grants SVB a first security interest in substantially all Company assets (other than our intellectual property). Pursuant to the new loan agreement, the Company is no longer required to maintain restricted cash accounts. At September 30, 2015 the principal balance of the Term Note was $6,000,000 and the principal balance of the Line of Credit was $0 . The following is a summary of long-term debt as of September 30, 2015 : September 30, Term Note, principal balance $ 6,000,000 Less unamortized debt issuance costs 27,884 Term Note, net 5,972,116 Less current maturities 833,333 Long-term portion $ 5,138,783 Principal maturities of the Term Note as of September 30, 2015 are as follows: 2016 - $1,333,333 ; 2017 - $2,000,000 ; 2018 - $2,000,000 ; 2019 - $666,667 .

Sale of Net Operating Loss

Sale of Net Operating Loss	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Sale of Net Operating Losses	Sale of Net Operating Losses In January 2014, we executed a sale of $22,301,643 of gross state NOL carryforwards resulting in the receipt of $1,813,941 . The Company transferred the NOL carryforwards through the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Incentive Plans	Equity Incentive Plans We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the “Stock Option Plans”). The Stock Option Plans are meant to provide additional incentive to officers, employees and consultants to remain in our employment. Options granted are generally exercisable for up to 10 years . On May 14, 2015, the stockholders voted to increase the number of shares reserved by the 2011 Plan to 2,650,000 shares of common stock. At September 30, 2015 , 825,100 shares remain available for future awards under the 2011 Plan and 93,616 shares remain available for future awards under the 2008 Plan. As of September 30, 2015 , no stock appreciation rights and 270,500 shares of restricted stock have been awarded under the Stock Option Plans. A summary of employee and non-employee stock option activity for the nine months ended September 30, 2015 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Number of Shares Weighted- Average Exercise Price Outstanding January 1, 2015 1,839,458 $ 10.58 8.49 $ 618,250 Granted 292,150 9.91 Exercised (4,371 ) 5.37 Canceled or expired (118,771 ) 9.63 Outstanding September 30, 2015 2,008,466 $ 10.55 7.93 $ 1,313,377 Exercisable September 30, 2015 881,027 $ 9.89 6.66 $ 862,492 Aggregate intrinsic value represents the difference between the estimated fair value of our common stock and the exercise price of outstanding, in-the-money options. The fair value of our common stock was $7.82 at September 30, 2015 and $6.68 at December 31, 2014 , based on the closing price on the NASDAQ Capital Market. During the three and nine months ended September 30, 2015 , we received approximately $1,000 and $24,000 , respectively, from the exercise of options. The options exercised during the three and nine months ended September 30, 2015 had a total intrinsic value of approximately $1,000 and $25,000 , respectively. As of September 30, 2015 , total unrecognized compensation cost related to non-vested stock options granted to employees was $5,536,069 which we expect to recognize over the next 3.32 years. As of September 30, 2015 , total unrecognized compensation cost related to non-vested stock options granted to non-employees was $536,138 which we expect to recognize over the next 2.25 years. The estimate of unrecognized non-employee compensation is based on the fair value of the non-vested options as of September 30, 2015 . The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model requires us to make assumptions and judgments about the variables used in the calculation, including the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period estimates are revised. No compensation cost is recorded for options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment , and volatility is based on an average of the historical volatilities of the common stock of three entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the small number of plan participants and the plan design which has monthly vesting after an initial cliff vesting period. The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Volatility 55.71 % 75.02 % 61.16 % 75.04 % Risk free interest rate 1.63 % 2.02 % 1.65 % 1.84 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 6.16 6.29 6.15 6.10 Weighted-average fair value of options granted during the period 5.41 6.13 5.65 6.86 In May 2014, we issued 200,000 options to our Director, Raju Chaganti, with an exercise price of $15.89 . See Note 11 for additional information. The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Volatility 69.56 % 71.30 % 69.97 % 71.87 % Risk free interest rate 2.02 % 2.43 % 2.11 % 2.53 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 8.58 9.58 8.84 9.79 Restricted stock awards have been granted to employees, directors and consultants as compensation for services. At September 30, 2015 , there was $838,146 of unrecognized compensation cost related to non-vested restricted stock granted to employees; we expect to recognize the cost over 2.64 years. At September 30, 2015 , there was $536 of unrecognized compensation cost related to non-vested restricted stock granted to non-employees; we expect to recognize the cost over 0.03 years. The following table summarizes the activities for our non-vested restricted stock awards for the nine months ended September 30, 2015 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2015 132,500 $ 8.14 Granted 43,000 9.70 Vested (33,333 ) 9.27 Canceled (10,000 ) $ 8.42 Non-vested at September 30, 2015 132,167 $ 8.36 The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Statement of Operations during the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of revenues $ 59,081 $ 26,200 $ 163,006 $ 67,109 Research and development 92,726 188,633 316,306 345,803 General and administrative 530,301 593,715 1,585,869 1,615,359 Sales and marketing 41,820 27,551 112,373 101,609 Total stock-based compensation $ 723,928 $ 836,099 $ 2,177,554 $ 2,129,880

Warrants

Warrants	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Warrants	Warrants We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. For all derivative warrants, in the event equity instruments are issued at a price lower than the exercise price of the warrant, the exercise price is adjusted to the price of the new equity instruments issued (price adjustment feature). For certain of these warrants, the number of shares underlying the warrant is also adjusted to an amount computed by dividing the proceeds of the warrant under its original terms by the revised exercise price (share adjustment feature). As of September 30, 2015 all warrants with a share adjustment feature have either expired or have been exercised. The derivative warrants are initially recorded as a warrant liability at fair value with a corresponding entry to the loan guarantee fee asset, debt discount, additional paid-in capital or expense dependent upon the service provided in exchange for the warrant grant. The following table summarizes the warrant activity for the nine months ended September 30, 2015 : Issued With / For Exercise Warrants 2015 Warrants Expired Warrants Outstanding September 30, 2015 Non-Derivative Warrants: Financing $ 10.00 243,334 — 243,334 Financing 15.00 436,079 — 436,079 Debt guarantee 15.00 352,312 — 352,312 Consulting 10.00 29,138 (19,138 ) 10,000 Total non-derivative warrants $ 13.78 B 1,060,863 (19,138 ) 1,041,725 Derivative Warrants: Financing $ 10.00 A 60,000 — 60,000 Series B pref. stock 10.00 A 15,015 — 15,015 Consulting 10.00 A 200 — 200 Total derivative warrants 10.00 B 75,215 — 75,215 Total $ 13.53 B 1,136,078 (19,138 ) 1,116,940 A These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 8. Assuming the offering described in Note 14 closes, the exercise price of these warrants will adjust to $4.00 on November 12, 2015. B Weighted-average exercise prices are as of September 30, 2015 .

Fair Value of Warrants

Fair Value of Warrants	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Warrants	Fair Value of Warrants The following table summarizes the derivative warrant activity subject to fair value accounting for the nine months ended September 30, 2015 : Issued with/for Fair value of Change in Fair value of Series B preferred stock $ 8,000 $ (6,000 ) $ 2,000 Financing 44,000 (12,000 ) 32,000 $ 52,000 $ (18,000 ) $ 34,000 The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue or exercise during the nine months ended September 30, 2015 and 2014 , and at September 30, 2015 and December 31, 2014 . Issued with Debt Guarantee Exercised During the Nine Months Ended September 30, 2014 Exercise price $ 10.00 Expected life (years) 0.60 Expected volatility 49.01 % Risk-free interest rate 0.08 % Expected dividend yield — % Issued with Series B Preferred Shares As of September 30, 2015 As of December 31, 2014 Exercised During the Nine Months Ended September 30, 2014 Exercise price $ 10.00 $ 10.00 $ 10.00 Expected life (years) 0.13 0.88 1.72 Expected volatility 57.27 % 49.95 % 46.60 % Risk-free interest rate — % 0.25 % 0.33 % Expected dividend yield — % — % — % Issued for Consulting As of September 30, 2015 As of December 31, 2014 Exercise price $ 10.00 $ 10.00 Expected life (years) 0.39 1.14 Expected volatility 49.38 % 49.25 % Risk-free interest rate 0.08 % 0.25 % Expected dividend yield — % — % Issued with Financing As of September 30, 2015 As of December 31, 2014 Exercised During the Nine Months Ended September 30, 2014 Exercise price $ 10.00 $ 10.00 $ 13.34 Expected life (years) 0.48 1.23 9.78 Expected volatility 49.99 % 50.23 % 74.70 % Risk-free interest rate 0.08 % 0.25 % 1.95 % Expected dividend yield — % — % — % The assumed Company stock price used in computing the fair value of warrants exercised during the nine months ended September 30, 2014 was $15.20 – $19.86 . In determining the fair value of warrants outstanding at each reporting date, the Company stock price was $7.82 at September 30, 2015 and $6.68 at December 31, 2014 based on the closing price on the NASDAQ Capital Market.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic of the FASB Accounting Standards Codification requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date. Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability. The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value: September 30, 2015 Total Quoted Prices in Significant Other Significant Warrant liability $ 34,000 $ — $ — $ 34,000 Gentris contingent consideration 45,000 — — 45,000 Note payable to VenturEast 626,101 — — 626,101 $ 705,101 $ — $ — $ 705,101 December 31, 2014 Total Quoted Prices in Significant Other Significant Warrant liability $ 52,000 $ — $ — $ 52,000 Gentris contingent consideration 293,400 — — 293,400 Note payable to VenturEast 534,828 — — 534,828 $ 880,228 $ — $ — $ 880,228 The warrant liability consists of stock warrants we issued that contain an exercise price adjustment feature. In accordance with derivative accounting for warrants, we calculated the fair value of warrants and the assumptions used are described in Note 8, “Fair Value of Warrants”. Realized and unrealized gains and losses related to the change in fair value of the warrant liability are included in Other income (expense) on the Statement of Operations. The value of the Gentris consideration was determined using a discounted cash flow of the expected payments required by the purchase agreement. During the nine months ended September 30, 2015 , we recognized a gain of approximately $162,000 due to the decrease in probability of paying the contingent consideration. The ultimate payment to VenturEast will be the value of 84,278 shares of common stock at the time of payment. The value of the note payable to VenturEast was determined using the fair value of our common stock less a discount for credit risk. During the three and nine months ended September 30, 2015 , we recognized a gain (loss) of approximately $315,000 and $(91,000) , respectively, due to the change in value of the note. Realized and unrealized gains and losses related to the change in fair value of the Gentris contingent consideration are included in general and administrative expense, while realized and unrealized gains and losses related to the VenturEast note are included in other income (expense) on the Consolidated Statement of Operations. A table summarizing the activity for the derivative warranty liability which is measured at fair value using Level 3 inputs is presented in Note 8. The following table summarizes the activity of the notes payable to VenturEast and Gentris consideration which were measured at fair value using Level 3 inputs: Note Payable Gentris Contingent to VenturEast Consideration Fair value at December 31, 2014 $ 534,828 $ 293,400 Change in fair value 91,273 (162,000 ) Partial settlement of liability $ — (86,400 ) Fair value at September 30, 2015 $ 626,101 $ 45,000

Joint Venture Agreement

Joint Venture Agreement	9 Months Ended
	Sep. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture Agreement	Joint Venture Agreement In November 2011 , we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). In exchange for our membership interest in the JV, we made an initial capital contribution of $1.0 million in October 2013. In addition, we issued 10,000 shares of our common stock to Mayo pursuant to our affiliation agreement and recorded an expense of approximately $175,000 . We also recorded additional expense of approximately $231,000 during the fourth quarter of 2013 related to shares issued to Mayo in November 2011 as the JV achieved certain performance milestones. In the third quarter of 2014, we made an additional $1.0 million capital contribution. The agreement also requires aggregate total capital contributions by us of up to an additional $4.0 million . We currently anticipate that we will make capital contributions of $1.0 million in the first quarter of 2016. The timing of the remaining installments is subject to the JV’s achievement of certain operational milestones agreed upon by the board of governors of the JV. In exchange for its membership interest, Mayo’s capital contribution will take the form of cash, staff, services, hardware and software resources, laboratory space and instrumentation, the fair market value of which will be approximately equal to $6.0 million . Mayo’s continued contribution will also be conditioned upon the JV’s achievement of certain milestones. Our share of the JV’s net loss was approximately $ 343,000 and $ 349,000 for the three months ended September 30, 2015 and 2014 , respectively, and $748,000 and $659,000 for the nine months ended September 30, 2015 and 2014 , respectively, and is included in research and development expense on the Consolidated Statement of Operations. We have a net receivable due from the JV of approximately $0 and $ 10,000 at September 30, 2015 and December 31, 2014 , respectively, which is included in other current assets in the Consolidated Balance Sheets. The joint venture is considered a variable interest entity under ASC 810-10, but we are not the primary beneficiary as we do not have the power to direct the activities of the JV that most significantly impact its performance. Our evaluation of ability to impact performance is based on our equal board membership and voting rights and day-to-day management functions which are performed by the Mayo personnel.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions John Pappajohn, a member of the Board of Directors and stockholder, had personally guaranteed our revolving line of credit with Wells Fargo Bank through March 31, 2014. As consideration for his guarantee, as well as each of the eight extensions of this facility through March 31, 2014, Mr. Pappajohn received warrants to purchase an aggregate of 1,051,506 shares of common stock of which Mr. Pappajohn assigned warrants to purchase 284,000 shares of common stock to certain third parties. Warrants to purchase 440,113 shares of common stock have been exercised by Mr. Pappajohn through September 30, 2015 . After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of these warrants outstanding retained by Mr. Pappajohn was 352,312 at $15.00 per share. In addition, John Pappajohn also had loaned us an aggregate of $6,750,000 (all of which was converted into 675,000 shares of common stock at the IPO price of $10.00 per share). In connection with these loans, Mr. Pappajohn received warrants to purchase an aggregate of 202,630 shares of common stock. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of warrants outstanding was 436,079 at $15.00 per share at September 30, 2015 . Effective January 6, 2014 , the Board of Directors appointed John Pappajohn to serve as the Chairman of the Board. As compensation for serving as the Chairman of the Board, the Company will pay Mr. Pappajohn $100,000 per year and granted to Mr. Pappajohn 25,000 restricted shares of the Company’s common stock, and options to purchase an aggregate of 100,000 shares of the Company's common stock. The options have a term of ten years from the date on which they were granted. The restricted stock and the options each vest in two equal installments on the one-year anniversary and the two-year anniversary of the date on which Mr. Pappajohn became the Chairman of the Board. On October 14, 2015 the Board of Directors granted John Pappajohn 2,500 restricted shares of the Company’s common stock and options to purchase an aggregate of 10,000 shares of the Company’s common stock as compensation for serving on the Board of Directors. The restricted stock vests on the one-year anniversary date of the grant and the stock options vest in two equal installments on the one-year anniversary and the two-year anniversary date of the grant. In August 2010, we entered into a consulting agreement with Equity Dynamics, Inc. (“EDI”), an entity controlled by John Pappajohn, pursuant to which EDI received a monthly fee of $10,000 . The consulting agreement was terminated effective March 31, 2014. Subsequently, the Company entered into a new consulting agreement with EDI effective April 1, 2014 pursuant to which it will receive a monthly fee of $10,000 . Total expenses for the three months ended September 30, 2015 and 2014 were $30,000 , and for the nine months ended September 30, 2015 and 2014 , total expenses were $ 90,000 . As of September 30, 2015 , we owed EDI $0 . On September 15, 2010, we entered into a three -year consulting agreement with Dr. Chaganti which was subsequently renewed through December 31, 2016 pursuant to which Dr. Chaganti receives $5,000 per month for providing consulting and technical support services. Total expenses for each of the three months ended September 30, 2015 and 2014 were $15,000 . Total expenses for each of the nine months ended September 30, 2015 and 2014 were $45,000 . Pursuant to the terms of the renewed consulting agreement, Dr. Chaganti received an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share vesting over a period of four years. Total non-cash stock-based compensation recognized under the consulting agreement for each of the three months ended September 30, 2015 and 2014 was $59,500 and $76,375 , respectively. Total non-cash stock-based compensation recognized under the consulting agreement for each of the nine months ended September 30, 2015 and 2014 was $220,625 and $288,500 , respectively. Also pursuant to the consulting agreement, Dr. Chaganti assigned to us all rights to any inventions which he may invent during the course of rendering consulting services to us. In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii) 1% of any net revenues we receive from any licensed sales of the invention. In 2015, we paid Dr. Chaganti $150,000 which was recognized as an expense in fiscal 2014 when three patents were issued. On October 14, 2015 the Board of Directors granted Dr. Chaganti 2,500 restricted shares of the Company’s common stock and options to purchase an aggregate of 10,000 shares of the Company’s common stock as compensation for serving on the Board of Directors. The restricted stock vests on the one-year anniversary date of the grant and the stock options vest in two equal installments on the one-year anniversary and the two-year anniversary date of the grant.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies In the normal course of business, the Company may become involved in various claims and legal proceedings. In the opinion of management, the ultimate liability or disposition thereof is not expected to have a material adverse effect on our financial condition, results of operations, or liquidity.

Cantor Sales Agreement

Cantor Sales Agreement	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Cantor Sales Agreement	Cantor Sales Agreement On July 15, 2015, the Company entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., (“Cantor”) as sales agent, pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $20.0 million . Subject to the terms and conditions of the Sales Agreement, Cantor will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market to sell shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. Under the Sales Agreement, Cantor may sell shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or, with the Company’s prior consent, any other method permitted by law, including in privately negotiated transactions. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by the Company from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement. During the three months ended September 30, 2015, the Company sold 2,800 shares of its common stock that resulted in net proceeds to the Company of approximately $34,000 . In July 2015, we temporarily suspended selling shares of common stock using the Sales Agreement. Furthermore, under the terms of our lock up agreement with Joseph Gunnar and Feltl, we may not resume selling our common stock under the Sales Agreement until 90 days after the public offering is consummated. See Note 14 for additional information regarding the public offering.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Events On November 6, 2015, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Joseph Gunnar & Co., LLC and Feltl and Company, Inc., as representatives of the several underwriters named in Schedule A to the Underwriting Agreement (the “Underwriters”). Pursuant to the terms and conditions of the Underwriting Agreement, the Company agreed to sell to the Underwriters 3,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”) and warrants on terms described below (the “Warrants”) to purchase up to an aggregate of 3,000,000 shares of Common Stock, at a combined price of $4.00 per share and accompanying Warrant, less underwriting discounts and commissions and has granted the Underwriters an option to purchase up to an additional 450,000 shares of Common Stock and/or Warrants within 45 days after the date of the Underwriting Agreement. The Company also agreed to pay a non-accountable expense allowance to the underwriters equal to 1.0% of the gross proceeds received in this offering as well as legal fees up to $60,000 ; however, an allowance shall not be paid in connection with the over-allotment option if the over-allotment option is exercised. The sale to the Underwriters is expected to close on November 12, 2015, subject to customary closing conditions. The Underwriting Agreement provides that the obligations of the Underwriters are subject to certain conditions precedent and that the Underwriters have agreed, severally and not jointly, to purchase all of the shares and Warrants being sold under the Underwriting Agreement if any such securities are purchased (other than the securities subject to the Underwriters’ option). Additionally, the Underwriting Agreement contains customary representations, warranties, and covenants by the Company and customary indemnification obligations of each of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended. In addition, subject to certain exceptions, each director and executive officer of the Company has entered into an agreement with the Underwriters not to sell, transfer or otherwise dispose of securities of the Company during the 90 -day period following the offering. The Company is also restricted in its ability to sell securities during such 90 -day period. The Company estimates that the net proceeds to the Company from the offering (exclusive of proceeds from the sale of shares and/or Warrants pursuant to any exercise of the Underwriters’ option described above and exclusive of proceeds, if any, from the exercise of the Warrants issued pursuant to the offering) will be approximately $10.5 million after deducting the underwriting discounts and commissions, and estimated offering expenses payable by the Company. The Company expects to use the net proceeds from the offering for contributions to its JV with Mayo, expansion of its sales and marketing capabilities, further research and development activities, expansion of business, strategic transactions and working capital and other general corporate purposes. No assurances can be given that all closing conditions will be satisfied and that the offering consummated on these terms, or at all. Each warrant will have an exercise price of $5.00 per share (subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders), will be exercisable upon issuance and will expire five years from the date of issuance (expected to be November 12, 2015). The foregoing description of the Underwriting Agreement and the Warrant does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement and the Warrant, copies of which are filed herewith as Exhibits 10.2 and 4.1. The provisions of the Underwriting Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreement and are not intended as a document for stockholders and the public to obtain factual information about the current state of affairs of the Company. Rather, stockholders and the public should look to other disclosures contained in the Company’s filings with the Commission.

Organization, Description of 20

Organization, Description of Business, Basis of Presentation and Acquisition (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 16, 2015. The consolidated balance sheet as of December 31, 2014, included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2015.
New Accounting Pronouncements	In the second quarter of 2015, we adopted ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. Previously, debt issuance costs were recorded as assets on the balance sheet. This update requires that debt issuance costs related to a debt liability be presented on the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. This update does not change the recognition and measurement of debt issuance costs and requires retrospective adoption.

Organization, Description of 21

Organization, Description of Business, Basis of Presentation and Acquisition (Tables)	9 Months Ended
	Sep. 30, 2015
BioServe [Member]
Business Acquisition [Line Items]
Schedule of recognized identified assets acquired and liabilities assumed	The fair value of the assets acquired and liabilities assumed as of August 18, 2014 are now as follows: Amount Accounts receivable $ 151,002 Other current assets 102,064 Fixed assets 488,481 Other assets 378,440 Goodwill 734,925 Current liabilities (758,614 ) Other liabilities (22,049 ) Total Purchase Price $ 1,074,249
BioServe and Gentris [Member]
Business Acquisition [Line Items]
Business acquisition, pro forma information	The following table provides certain pro forma financial information for the Company as if the acquisitions of Gentris and BioServe discussed above occurred on January 1, 2014: Three Months Ended Nine Months Ended September 30, 2014 September 30, 2014 Revenue $ 3,493,345 $ 10,329,910 Net loss (6,039,858 ) (13,325,068 ) Basic net loss per share $ (0.63 ) $ (1.40 ) Diluted net loss per share (0.64 ) (1.43 )
Response Genetics, Inc. [Member]
Business Acquisition [Line Items]
Schedule of recognized identified assets acquired and liabilities assumed	The preliminary allocation of the purchase price of the fair value of the assets acquired and liabilities assumed as of October 9, 2015 are as follows: Amount Accounts receivable $ 350,000 Prepaid expenses and other current assets 500,000 Property and equipment 1,000,000 Intangible assets 550,000 Goodwill 11,550,000 Accrued expenses (425,000 ) Obligations under capital leases (125,000 ) Total Purchase Price $ 13,400,000
Business acquisition, pro forma information	The following table provides certain pro forma financial information for the Company as if the acquisition of Response Genetics discussed above occurred on January 1, 2014: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Revenue $ 6,879,587 $ 7,686,841 $ 23,043,458 $ 18,805,055 Net loss (10,353,822 ) (8,181,903 ) (27,522,585 ) (21,450,482 ) Basic net loss per share $ (0.98 ) $ (0.79 ) $ (2.62 ) $ (2.11 ) Diluted net loss per share (1.00 ) (0.80 ) (2.62 ) (2.14 )

Revenue and Accounts Receivab22

Revenue and Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Schedule of Revenue by Payor Type	Revenue by service type for the three and nine months ended September 30, 2015 and 2014 is comprised of the following: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Biopharma Services $ 2,608,427 $ 1,930,799 8,614,441 $ 2,830,687 Clinical Services 1,149,241 1,237,831 3,273,585 3,279,988 Discovery Services 242,664 53,220 667,780 53,220 $ 4,000,332 $ 3,221,850 $ 12,555,806 $ 6,163,895
Schedule of Accounts Receivable by Payor Type	Accounts receivable by service type at September 30, 2015 and December 31, 2014 consists of the following: September 30, December 31, Biopharma Services $ 2,879,064 $ 3,203,335 Clinical Services 2,401,775 1,925,176 Discovery Services 348,344 151,285 Allowance for doubtful accounts (464,090 ) (251,176 ) $ 5,165,093 $ 5,028,620 Allowance for Doubtful Accounts Balance, December 31, 2014 $ 251,176 Bad debt provision 212,914 Balance, September 30, 2015 $ 464,090
Schedule of Clinical Services Revenue (as a percent of total revenue)	The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 12% 9% 8% 13% Other insurers 7% 14% 7% 21% Other healthcare facilities 9% 15% 8% 19% 28% 38% 23% 53%

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic net loss and diluted net loss per share data were computed as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net (loss) for basic earnings per share $ (5,212,014 ) $ (4,797,062 ) $ (14,470,164 ) $ (11,469,659 ) Change in fair value of warrant liability 214,000 129,000 18,000 324,000 Net (loss) for diluted earnings per share $ (5,426,014 ) $ (4,926,062 ) $ (14,488,164 ) $ (11,793,659 ) Denominator: Weighted-average basic common shares outstanding 9,726,067 9,575,789 9,714,824 9,386,613 Assumed conversion of dilutive securities: Common stock purchase warrants 1,530 — 1,390 16,632 Potentially dilutive common shares 1,530 — 1,390 16,632 Denominator for diluted earnings per share – adjusted weighted-average shares 9,727,597 9,575,789 9,716,214 9,403,245 Basic net (loss) per share $ (0.54 ) $ (0.50 ) $ (1.49 ) $ (1.22 ) Diluted net (loss) per share $ (0.56 ) $ (0.51 ) $ (1.49 ) $ (1.25 )
Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation	The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Common stock purchase warrants 1,041,725 1,531,696 1,041,725 1,531,696 Stock options 2,008,466 1,461,724 2,008,466 1,461,724 Restricted shares of common stock 132,167 105,833 132,167 105,833 3,182,358 3,099,253 3,182,358 3,099,253

Bank Term Note and Line of Cr24

Bank Term Note and Line of Credit (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	The following is a summary of long-term debt as of September 30, 2015 : September 30, Term Note, principal balance $ 6,000,000 Less unamortized debt issuance costs 27,884 Term Note, net 5,972,116 Less current maturities 833,333 Long-term portion $ 5,138,783

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Employee and Nonemployee Stock Option Activity	A summary of employee and non-employee stock option activity for the nine months ended September 30, 2015 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Number of Shares Weighted- Average Exercise Price Outstanding January 1, 2015 1,839,458 $ 10.58 8.49 $ 618,250 Granted 292,150 9.91 Exercised (4,371 ) 5.37 Canceled or expired (118,771 ) 9.63 Outstanding September 30, 2015 2,008,466 $ 10.55 7.93 $ 1,313,377 Exercisable September 30, 2015 881,027 $ 9.89 6.66 $ 862,492
Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted	The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Volatility 55.71 % 75.02 % 61.16 % 75.04 % Risk free interest rate 1.63 % 2.02 % 1.65 % 1.84 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 6.16 6.29 6.15 6.10 Weighted-average fair value of options granted during the period 5.41 6.13 5.65 6.86 The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Volatility 69.56 % 71.30 % 69.97 % 71.87 % Risk free interest rate 2.02 % 2.43 % 2.11 % 2.53 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 8.58 9.58 8.84 9.79
Nonvested Restricted Stock Shares Activity	The following table summarizes the activities for our non-vested restricted stock awards for the nine months ended September 30, 2015 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2015 132,500 $ 8.14 Granted 43,000 9.70 Vested (33,333 ) 9.27 Canceled (10,000 ) $ 8.42 Non-vested at September 30, 2015 132,167 $ 8.36
Effects of Stock-Based Compensation Related to Stock Option Awards	The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Statement of Operations during the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of revenues $ 59,081 $ 26,200 $ 163,006 $ 67,109 Research and development 92,726 188,633 316,306 345,803 General and administrative 530,301 593,715 1,585,869 1,615,359 Sales and marketing 41,820 27,551 112,373 101,609 Total stock-based compensation $ 723,928 $ 836,099 $ 2,177,554 $ 2,129,880

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Warrant Activity	The following table summarizes the warrant activity for the nine months ended September 30, 2015 : Issued With / For Exercise Warrants 2015 Warrants Expired Warrants Outstanding September 30, 2015 Non-Derivative Warrants: Financing $ 10.00 243,334 — 243,334 Financing 15.00 436,079 — 436,079 Debt guarantee 15.00 352,312 — 352,312 Consulting 10.00 29,138 (19,138 ) 10,000 Total non-derivative warrants $ 13.78 B 1,060,863 (19,138 ) 1,041,725 Derivative Warrants: Financing $ 10.00 A 60,000 — 60,000 Series B pref. stock 10.00 A 15,015 — 15,015 Consulting 10.00 A 200 — 200 Total derivative warrants 10.00 B 75,215 — 75,215 Total $ 13.53 B 1,136,078 (19,138 ) 1,116,940 A These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 8. Assuming the offering described in Note 14 closes, the exercise price of these warrants will adjust to $4.00 on November 12, 2015. B Weighted-average exercise prices are as of September 30, 2015 .

Fair Value of Warrants (Tables)

Fair Value of Warrants (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Derivative Warrant Activity	The following table summarizes the derivative warrant activity subject to fair value accounting for the nine months ended September 30, 2015 : Issued with/for Fair value of Change in Fair value of Series B preferred stock $ 8,000 $ (6,000 ) $ 2,000 Financing 44,000 (12,000 ) 32,000 $ 52,000 $ (18,000 ) $ 34,000
Assumptions Used in Computing Fair Value of Derivative Warrants	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue or exercise during the nine months ended September 30, 2015 and 2014 , and at September 30, 2015 and December 31, 2014 . Issued with Debt Guarantee Exercised During the Nine Months Ended September 30, 2014 Exercise price $ 10.00 Expected life (years) 0.60 Expected volatility 49.01 % Risk-free interest rate 0.08 % Expected dividend yield — % Issued with Series B Preferred Shares As of September 30, 2015 As of December 31, 2014 Exercised During the Nine Months Ended September 30, 2014 Exercise price $ 10.00 $ 10.00 $ 10.00 Expected life (years) 0.13 0.88 1.72 Expected volatility 57.27 % 49.95 % 46.60 % Risk-free interest rate — % 0.25 % 0.33 % Expected dividend yield — % — % — % Issued for Consulting As of September 30, 2015 As of December 31, 2014 Exercise price $ 10.00 $ 10.00 Expected life (years) 0.39 1.14 Expected volatility 49.38 % 49.25 % Risk-free interest rate 0.08 % 0.25 % Expected dividend yield — % — % Issued with Financing As of September 30, 2015 As of December 31, 2014 Exercised During the Nine Months Ended September 30, 2014 Exercise price $ 10.00 $ 10.00 $ 13.34 Expected life (years) 0.48 1.23 9.78 Expected volatility 49.99 % 50.23 % 74.70 % Risk-free interest rate 0.08 % 0.25 % 1.95 % Expected dividend yield — % — % — %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Financial Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value: September 30, 2015 Total Quoted Prices in Significant Other Significant Warrant liability $ 34,000 $ — $ — $ 34,000 Gentris contingent consideration 45,000 — — 45,000 Note payable to VenturEast 626,101 — — 626,101 $ 705,101 $ — $ — $ 705,101 December 31, 2014 Total Quoted Prices in Significant Other Significant Warrant liability $ 52,000 $ — $ — $ 52,000 Gentris contingent consideration 293,400 — — 293,400 Note payable to VenturEast 534,828 — — 534,828 $ 880,228 $ — $ — $ 880,228
Schedule of Fair Value Notes Payable and Contingent Consideration of Business Acquisitions	The following table summarizes the activity of the notes payable to VenturEast and Gentris consideration which were measured at fair value using Level 3 inputs: Note Payable Gentris Contingent to VenturEast Consideration Fair value at December 31, 2014 $ 534,828 $ 293,400 Change in fair value 91,273 (162,000 ) Partial settlement of liability $ — (86,400 ) Fair value at September 30, 2015 $ 626,101 $ 45,000

Organization, Description of 29

Organization, Description of Business, Basis of Presentation and Acquisition - Additional Information (Detail) - USD ($)	Oct. 09, 2015	Aug. 18, 2014	Jul. 16, 2014	Sep. 30, 2015	Sep. 30, 2015
Gentris [Member]
Business Acquisition [Line Items]
Consideration transferred			$ 4,800,000
Goodwill impairment loss					$ 0
BioServe [Member]
Business Acquisition [Line Items]
Consideration transferred		$ 1,100,000
Goodwill impairment loss					0
Adjustment to goodwill					193,000
Adjustment to fixed assets					(136,000)
Adjustment to other assets					(38,000)
Adjustment to other current assets					(19,000)
BioServe and Gentris [Member]
Acquisition [Abstract]
Pro forma revenue of acquirees since acquisition date				$ 1,728,238	5,357,382
Pro forma earnings (loss) of acquirees since acquisition date				$ (1,043,224)	$ (2,202,254)
Subsequent Event [Member] | Response Genetics, Inc. [Member]
Business Acquisition [Line Items]
Consideration transferred	$ 13,400,000
Acquisition [Abstract]
Consideration transferred, amount paid in cash	$ 7,000,000
Consideration transferred, common stock paid (in shares)	788,584
Consideration transferred, common stock value	$ 6,400,000

Organization, Description of 30

Organization, Description of Business, Basis of Presentation and Acquisition - BioServe Assets & Liabilities Assumed (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Aug. 18, 2014
Business Acquisition [Line Items]
Goodwill	$ 3,187,495	$ 3,187,495
BioServe [Member]
Business Acquisition [Line Items]
Accounts receivable			$ 151,002
Other current assets			102,064
Fixed assets			488,481
Other assets			378,440
Goodwill			734,925
Current liabilities			(758,614)
Other liabilities			(22,049)
Total Purchase Price			$ 1,074,249

Organization, Description of 31

Organization, Description of Business, Basis of Presentation and Acquisition - Pro Forma (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
BioServe and Gentris [Member]
Pro Forma Financial Information
Revenue		$ 3,493,345		$ 10,329,910
Net loss		$ (6,039,858)		$ (13,325,068)
Basic net loss per share (usd per share)		$ (0.63)		$ (1.40)
Dilutive net loss per share (usd per share)		$ (0.64)		$ (1.43)
Response Genetics, Inc. [Member]
Pro Forma Financial Information
Revenue	$ 6,879,587	$ 7,686,841	$ 23,043,458	$ 18,805,055
Net loss	$ (10,353,822)	$ (8,181,903)	$ (27,522,585)	$ (21,450,482)
Basic net loss per share (usd per share)	$ (0.98)	$ (0.79)	$ (2.62)	$ (2.11)
Dilutive net loss per share (usd per share)	$ (1)	$ (0.80)	$ (2.62)	$ (2.14)

Organization, Description of 32

Organization, Description of Business, Basis of Presentation and Acquisition - Response Genetics Assets & Liabilities Assumed (Details) - USD ($)	Oct. 09, 2015	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 3,187,495	$ 3,187,495
Subsequent Event [Member] | Response Genetics, Inc. [Member]
Business Acquisition [Line Items]
Accounts receivable	$ 350,000
Prepaid expenses and other current assets	500,000
Property and equipment	1,000,000
Intangible assets	550,000
Goodwill	11,550,000
Accrued expenses	(425,000)
Obligations under capital leases	(125,000)
Total Purchase Price	$ 13,400,000

Revenue and Accounts Receivab33

Revenue and Accounts Receivable - Schedule of Revenue by Service Type (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 4,000,332	$ 3,221,850	$ 12,555,806	$ 6,163,895
Biopharma Services [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	2,608,427	1,930,799	8,614,441	2,830,687
Clinical Services [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	1,149,241	1,237,831	3,273,585	3,279,988
Discovery Services [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 242,664	$ 53,220	$ 667,780	$ 53,220

Revenue and Accounts Receivab34

Revenue and Accounts Receivable - Schedule of Accounts Receivable by Service Type (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts	$ (464,090)	$ (251,176)
Accounts receivable, net	5,165,093	5,028,620
Biopharma Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	2,879,064	3,203,335
Clinical Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	2,401,775	1,925,176
Discovery Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 348,344	$ 151,285

Revenue and Accounts Receivab35

Revenue and Accounts Receivable - Allowance for Doubtful Accounts (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance, December 31, 2014	$ 251,176
Bad debt provision	212,914	$ 0
Balance, September 30, 2015	$ 464,090

Revenue and Accounts Receivab36

Revenue and Accounts Receivable - Schedule of Product Information (Details) - Payor [Member] - Sales Revenue, Net [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Product Information [Line Items]
Percentage of revenue	28.00%	38.00%	23.00%	53.00%
Medicare [Member]
Product Information [Line Items]
Percentage of revenue	12.00%	9.00%	8.00%	13.00%
Other insurers [Member]
Product Information [Line Items]
Percentage of revenue	7.00%	14.00%	7.00%	21.00%
Other healthcare facilities [Member]
Product Information [Line Items]
Percentage of revenue	9.00%	15.00%	8.00%	19.00%

Revenue and Accounts Receivab37

Revenue and Accounts Receivable - Additional Information (Detail) - company	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of companies accounted for approximately 10% or more of our revenue	2	2	2	1
Payor [Member] | Testing Volume [Member] | Clinical Testing [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	59.00%	59.00%	80.00%	58.00%
Payor [Member] | Testing Volume [Member] | Community Hospitals [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	27.00%	45.00%	31.00%	40.00%
Payor [Member] | Sales [Member] | 10% or More Clinical Revenue [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark			22.00%
Payor [Member] | Sales [Member] | Customer One [Member] | 10% or More Clinical Revenue [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	15.00%	17.00%	23.00%
Payor [Member] | Sales [Member] | Customer Two [Member] | 10% or More Clinical Revenue [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	11.00%	12.00%	11.00%

Earnings Per Share - Summary of

Earnings Per Share - Summary of Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Net (loss) for basic earnings per share	$ (5,212,014)	$ (4,797,062)	$ (14,470,164)	$ (11,469,659)
Change in fair value of warrant liability	214,000	129,000	18,000	324,000
Net (loss) for diluted earnings per share	$ (5,426,014)	$ (4,926,062)	$ (14,488,164)	$ (11,793,659)
Weighted-average basic common shares outstanding (in shares)	9,726,067	9,575,789	9,714,824	9,386,613
Common stock purchase warrants (in shares)	1,530	0	1,390	16,632
Potentially dilutive common shares (in shares)	1,530	0	1,390	16,632
Denominator for diluted earnings per share – adjusted weighted-average shares (in shares)	9,727,597	9,575,789	9,716,214	9,403,245
Basic net (loss) per share (usd per share)	$ (0.54)	$ (0.50)	$ (1.49)	$ (1.22)
Diluted net (loss) per share (usd per share)	$ (0.56)	$ (0.51)	$ (1.49)	$ (1.25)

Earnings Per Share - Summary 39

Earnings Per Share - Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	3,182,358	3,099,253	3,182,358	3,099,253
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	1,041,725	1,531,696	1,041,725	1,531,696
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	2,008,466	1,461,724	2,008,466	1,461,724
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	132,167	105,833	132,167	105,833

Bank Term Note and Line of Cr40

Bank Term Note and Line of Credit - Additional Information (Details) - USD ($)	May. 07, 2015	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Line of credit, principal balance		$ 0	$ 6,000,000
Secured Debt [Member]
Debt Instrument [Line Items]
Term Note, principal balance	$ 6,000,000
Periodic principal payment	$ 167,000
Stated interest rate, minimum	5.25%
Deferred interest due upon maturity	$ 180,000
Term Note, principal balance	$ 6,000,000	6,000,000
Maturities of Long-term Debt [Abstract]
2,016		1,333,333
2,017		2,000,000
2,018		2,000,000
2,019		666,667
Secured Debt [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.00%
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity	$ 4,000,000
Line of credit, maximum borrowing capacity, percent of accounts receivable	80.00%
Line of credit, principal balance		$ 0
Line of Credit [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%

Bank Term Note and Line of Cr41

Bank Term Note and Line of Credit - Schedule of Long-Term Debt (Details) - Secured Debt [Member] - USD ($)	Sep. 30, 2015	May. 07, 2015
Debt Instrument [Line Items]
Term Note, principal balance	$ 6,000,000	$ 6,000,000
Less unamortized debt issuance costs	27,884
Term Note, net	5,972,116
Less current maturities	833,333
Long-term portion	$ 5,138,783

Sale of Net Operating Loss - Ad

Sale of Net Operating Loss - Additional Information (Detail) - State and Local Jurisdiction [Member]	1 Months Ended
	Jan. 31, 2014USD ($)
Tax Credit Carryforward [Line Items]
NOL carryforwards sold	$ 22,301,643
Proceeds from sale of NOL carryforwards	$ 1,813,941

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail)	1 Months Ended	3 Months Ended		9 Months Ended
	May. 31, 2014$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)stock_plan$ / sharesshares	Sep. 30, 2014USD ($)	May. 14, 2015shares	Dec. 31, 2014$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | stock_plan				2
Options granted maximum exercisable period				10 years
Stock appreciation rights | shares				0
Restricted stock awarded | shares				270,500
Fair value of common stock | $ / shares		$ 7.82		$ 7.82			$ 6.68
Proceeds from option exercises		$ 1,000		$ 23,480	$ 79,018
Intrinsic value			$ 1,000		$ 25,000
Non-Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted		536,138		$ 536,138
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)				2 years 3 months
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted		$ 5,536,069		$ 5,536,069
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)				3 years 3 months 26 days
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares under stock options issued | shares	200,000
Exercise price of options exchanged | $ / shares	$ 15.89
2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized | shares						2,650,000
Shares available for future awards | shares		825,100		825,100
2008 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future awards | shares		93,616		93,616
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)				2 years 7 months 21 days
Unrecognized compensation cost		$ 838,146		$ 838,146
Restricted Stock [Member] | Non-Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)				11 days
Unrecognized compensation cost		$ 536		$ 536

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Employee and Nonemployee Stock Option Activity (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Options Outstanding, Number of Shares Outstanding
Outstanding, beginning balance (in shares)	1,839,458
Granted (in shares)	292,150
Exercised (in shares)	(4,371)
Canceled or expired (in shares)	(118,771)
Outstanding, ending balance (in shares)	2,008,466	1,839,458
Exercisable	881,027
Options Outstanding, Weighted-Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 10.58
Granted (in dollars per share)	9.91
Exercised (In dollars per share)	5.37
Cancelled or expired (in dollars per share)	9.63
Outstanding, ending balance (in dollars per share)	10.55	$ 10.58
Exercisable (in dollars per share)	$ 9.89
Weighted-Average Remaining Contractual Term (in years)
Outstanding	7 years 11 months 5 days	8 years 5 months 27 days
Exercisable	6 years 7 months 28 days
Aggregate Intrinsic Value
Outstanding, beginning balance	$ 618,250
Outstanding, ending balance	1,313,377	$ 618,250
Exercisable	$ 862,492

Equity Incentive Plans - Weight

Equity Incentive Plans - Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	55.71%	75.02%	61.16%	75.04%
Risk free interest rate	1.63%	2.02%	1.65%	1.84%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Term (years)	6 years 1 month 28 days	6 years 3 months 15 days	6 years 1 month 24 days	6 years 1 month 6 days
Weighted-average fair value of options granted during the period	$ 5.41	$ 6.13	$ 5.65	$ 6.86
Non-Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	69.56%	71.30%	69.97%	71.87%
Risk free interest rate	2.02%	2.43%	2.11%	2.53%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Term (years)	8 years 6 months 29 days	9 years 6 months 29 days	8 years 10 months 2 days	9 years 9 months 15 days

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock Award Activity (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Number of Shares (in shares):
Non-vested at January 1, 2015 (in shares)	132,500
Granted (in shares)	43,000
Vested (in shares)	(33,333)
Canceled (in shares)	(10,000)
Non-vested at September 30, 2015 (in shares)	132,167
Weighted-Average Grant Date Fair Value (in dollars per share):
Non-vested at January 1, 2015 (in dollars per share) | $ / shares	$ 8.14
Granted (in dollars per share) | $ / shares	9.70
Vested (in dollars per share) | $ / shares	9.27
Canceled (in dollars per share) | $ / shares	8.42
Non-vested at September 30, 2015 (in dollars per share) | $ / shares	$ 8.36

Equity Incentive Plans - Effect

Equity Incentive Plans - Effects of Stock-Based Compensation Related to Stock Option Awards (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 723,928	$ 836,099	$ 2,177,554	$ 2,129,880
Cost of Revenues [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	59,081	26,200	163,006	67,109
Research and Development [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	92,726	188,633	316,306	345,803
General and Administrative [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	530,301	593,715	1,585,869	1,615,359
Sales and Marketing [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 41,820	$ 27,551	$ 112,373	$ 101,609

Warrants - Summary of Warrant A

Warrants - Summary of Warrant Activity (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2015	Nov. 12, 2015
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 13.53
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	1,136,078
Warrants exercised (in shares)	(19,138)
Warrants outstanding, ending balance (in shares)	1,116,940
Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 13.78
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	1,060,863
Warrants exercised (in shares)	(19,138)
Warrants outstanding, ending balance (in shares)	1,041,725
Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	75,215
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	75,215
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 15
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	352,312
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	352,312
Series B Preferred Stock [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	15,015
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	15,015
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	243,334
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	243,334
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 15
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	436,079
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	436,079
Consulting [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	29,138
Warrants exercised (in shares)	(19,138)
Warrants outstanding, ending balance (in shares)	10,000
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	60,000
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	60,000
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	200
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	200
Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant (usd per share)		$ 4

Fair Value of Warrants - Additi

Fair Value of Warrants - Additional Information (Detail) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Fair value of warrants issue price (usd per share)	$ 7.82	$ 6.68
Minimum [Member]
Class of Warrant or Right [Line Items]
Fair value of stock prices in computing fair value for warrants exercised (usd per share)	15.20
Maximum [Member]
Class of Warrant or Right [Line Items]
Fair value of stock prices in computing fair value for warrants exercised (usd per share)	$ 19.86

Fair Value of Warrants - Summar

Fair Value of Warrants - Summary of Derivative Warrant Activity (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2014	$ 52,000
Change in fair value of warrant liability	(18,000)	$ (324,000)
Fair value of warrants outstanding as of September 30, 2015	34,000
Financing [Member]
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2014	44,000
Change in fair value of warrant liability	(12,000)
Fair value of warrants outstanding as of September 30, 2015	32,000
Series B Preferred Stock [Member]
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2014	8,000
Change in fair value of warrant liability	(6,000)
Fair value of warrants outstanding as of September 30, 2015	$ 2,000

Fair Value of Warrants - Assump

Fair Value of Warrants - Assumptions Used in Computing Fair Value of Derivative Warrants (Detail) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Exercise price (usd per share)	$ 10	$ 10	$ 10
Expected life (years)	1 month 17 days	1 year 8 months 19 days	10 months 17 days
Expected volatility (as percent)	57.27%	46.60%	49.95%
Risk-free interest rate (as percent)	0.00%	0.33%	0.25%
Expected dividend yield (as percent)	0.00%	0.00%	0.00%
Debt Guarantee [Member]
Class of Warrant or Right [Line Items]
Exercise price (usd per share)		$ 10
Expected life (years)		7 months 6 days
Expected volatility (as percent)		49.01%
Risk-free interest rate (as percent)		0.08%
Expected dividend yield (as percent)		0.00%
Consulting [Member]
Class of Warrant or Right [Line Items]
Exercise price (usd per share)	$ 10		$ 10
Expected life (years)	4 months 21 days		1 year 1 month 21 days
Expected volatility (as percent)	49.38%		49.25%
Risk-free interest rate (as percent)	0.08%		0.25%
Expected dividend yield (as percent)	0.00%		0.00%
Financing [Member]
Class of Warrant or Right [Line Items]
Exercise price (usd per share)	$ 10	$ 13.34	$ 10
Expected life (years)	5 months 23 days	9 years 9 months 11 days	1 year 2 months 23 days
Expected volatility (as percent)	49.99%	74.70%	50.23%
Risk-free interest rate (as percent)	0.08%	1.95%	0.25%
Expected dividend yield (as percent)	0.00%	0.00%	0.00%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair value measurements, recurring [Member] - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 34,000	$ 52,000
Total liabilities fair value	705,101	880,228
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Total liabilities fair value	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Total liabilities fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	34,000	52,000
Total liabilities fair value	705,101	880,228
Gentris [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	45,000	293,400
Gentris [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Gentris [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Gentris [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	45,000	293,400
BioServe [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	626,101	534,828
BioServe [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	0	0
BioServe [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	0	0
BioServe [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	$ 626,101	$ 534,828

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable	$ 315,453	$ 0	$ (90,714)	$ 0
Gentris [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable			162,000	0
BioServe [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable			(90,714)	$ 0
VenturEast [Member] | BioServe [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable	$ 315,000		$ (91,000)
Number of shares associated with notes payable	84,278

Fair Value Measurements - Sum54

Fair Value Measurements - Summary of Fair Value of Notes Payable (Details) - Contingent Consideration Liability [Member] - Fair Value, Inputs, Level 3 [Member] - Fair value measurements, recurring [Member]	9 Months Ended
	Sep. 30, 2015USD ($)
BioServe [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning balance	$ 534,828
Change in fair value	91,273
Partial settlement of liability	0
Ending balance	626,101
Gentris [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning balance	293,400
Change in fair value	(162,000)
Partial settlement of liability	(86,400)
Ending balance	$ 45,000

Joint Venture Agreement - Addit

Joint Venture Agreement - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended				9 Months Ended
	Oct. 31, 2013	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	May. 31, 2013
Schedule of Equity Method Investments [Line Items]
Investment in JV (up to)						$ 0	$ 1,000,000
Common stock, shares issued (in shares)	10,000		9,861,340			9,861,340		9,821,169
Additional expense related to shares issued	$ 175,000				$ 231,000
Joint venture net loss						$ 747,519	659,426
Joint Venture Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Percentage of outstanding membership interests in joint venture									50.00%
Investment in JV (up to)	$ 1,000,000			$ 1,000,000
Fair value of capital contribution in joint venture			$ 6,000,000			6,000,000
Joint Venture Agreement [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Investment in JV (up to)						4,000,000
Joint Venture Agreement [Member] | Scenario, Forecast [Member]
Schedule of Equity Method Investments [Line Items]
Investment in JV (up to)		$ 1,000,000
Research and Development [Member]
Schedule of Equity Method Investments [Line Items]
Joint venture net loss			343,000	$ 349,000		748,000	$ 659,000
Equity Method Investee [Member]
Schedule of Equity Method Investments [Line Items]
Due from related parties, current			$ 0			$ 0		$ 10,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Oct. 14, 2015installmentshares	Apr. 01, 2014USD ($)	Jan. 06, 2014USD ($)installmentshares	Sep. 15, 2010USD ($)	Aug. 31, 2010USD ($)	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Mar. 31, 2014extensionshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)patentshares	Oct. 31, 2013shares
Related Party Transaction [Line Items]
Number of revolving line of credit extensions facility | extension								8
Warrants exercised (in shares)									19,138
Convertible shares issued to common stock						9,861,340			9,861,340		9,821,169	10,000
Shares granted (in shares)									292,150
Consulting agreement period				3 years
Financial Guarantee [Member]
Related Party Transaction [Line Items]
Common stock purchased								284,000
Warrants exercised (in shares)									440,113
John Pappajohn [Member]
Related Party Transaction [Line Items]
Common stock purchased						202,630			202,630
Warrants adjusted in conjunction with IPO						436,079			436,079
Warrants outstanding per share (usd per share) | $ / shares						$ 15			$ 15
Additional amount of loan received | $									$ 6,750,000
John Pappajohn [Member] | Financial Guarantee [Member]
Related Party Transaction [Line Items]
Common stock purchased								1,051,506
Warrants adjusted in conjunction with IPO						352,312			352,312
Warrants outstanding per share (usd per share) | $ / shares						$ 15			$ 15
John Pappajohn [Member] | IPO [Member]
Related Party Transaction [Line Items]
Convertible shares issued to common stock						675,000			675,000
Conversion price of notes | $ / shares						$ 10			$ 10
Chairman of the Board [Member]
Related Party Transaction [Line Items]
Compensation for serving as chairman of the board | $			$ 100,000
Chairman of the Board [Member] | 2011 Equity Plan [Member]
Related Party Transaction [Line Items]
Shares granted (in shares)			100,000
Equity Dynamics, Inc. [Member]
Related Party Transaction [Line Items]
Agreement with related party, fee | $		$ 10,000			$ 10,000
Agreement with related party, consulting fee | $						$ 30,000	$ 30,000		$ 90,000	$ 90,000
Due to related party | $						0			0
Dr. Chaganti [Member]
Related Party Transaction [Line Items]
Agreement with related party, consulting fee | $						$ 15,000	15,000		45,000	45,000
Consulting and advisory services fee | $									$ 5,000
Agreement with related party, one-time payment required | $				$ 50,000
Agreement with related party, percentage of net revenues required to be paid				1.00%
Patents expense paid | $											$ 150,000
Number of patents were issued | patent											3
Dr. Chaganti [Member] | 2011 Equity Plan [Member]
Related Party Transaction [Line Items]
Shares granted (in shares)									200,000
Common stock, shares purchased price per share | $ / shares						$ 15.89			$ 15.89
Award vesting period									4 years
Compensation for Serving as Chairman of Board [Member] | Chairman of the Board [Member]
Related Party Transaction [Line Items]
Options granted period			10 years
Number of installments | installment			2
Consulting and Advisory Agreement [Member]
Related Party Transaction [Line Items]
Non-cash stock-based compensation expense | $						$ 59,500	$ 76,375		$ 220,625	$ 288,500
Restricted Stock [Member]
Related Party Transaction [Line Items]
Granted (in shares)									43,000
Restricted Stock [Member] | Chairman of the Board [Member]
Related Party Transaction [Line Items]
Granted (in shares)			25,000
Subsequent Event [Member] | Compensation for Serving on Board of Directors [Member] | Dr. Chaganti [Member]
Related Party Transaction [Line Items]
Shares granted (in shares)	10,000
Number of installments | installment	2
Subsequent Event [Member] | Restricted Stock [Member] | Compensation for Serving as Chairman of Board [Member] | Chairman of the Board [Member]
Related Party Transaction [Line Items]
Granted (in shares)	2,500
Shares granted (in shares)	10,000
Number of installments | installment	2
Subsequent Event [Member] | Restricted Stock [Member] | Compensation for Serving on Board of Directors [Member] | Dr. Chaganti [Member]
Related Party Transaction [Line Items]
Granted (in shares)	2,500

Cantor Sales Agreement (Details

Cantor Sales Agreement (Details) - USD ($)	Jul. 15, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Class of Stock [Line Items]
Stock issued during period, shares, new issues		2,800
Proceeds from offering of common stock, net of offering costs		$ 34,000	$ 33,526	$ 0
Lock up agreement term	90 days
Cantor Fitzgerald & Co. [Member]
Class of Stock [Line Items]
Common stock maximum offering price (up to)	$ 20,000,000
Sales agent commission rate	3.00%

Subsequent Event (Details)

Subsequent Event (Details) - USD ($)	Nov. 06, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Nov. 12, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Stock issued during period, shares, new issues		2,800
Common stock, par value (usd per share)		$ 0.0001	$ 0.0001			$ 0.0001
Proceeds from offering of common stock, net of offering costs		$ 34,000	$ 33,526	$ 0
Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price of warrant (usd per share)					$ 4
Underwriting Agreement [Member] | Joseph Gunnar & Co., LLC and Feltl and Company, Inc. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, par value (usd per share)	$ 0.0001
Warrants issued to purchase common stock	3,000,000
Sale of stock, non-accountable expense allowance rate	1.00%
Legal fees (up to)	$ 60,000
Offering period	90 days
Proceeds from offering of common stock, net of offering costs	$ 10,500,000
Exercise price of warrant (usd per share)	$ 5
Warrants issued, expiration period	5 years
Over-Allotment Option [Member] | Joseph Gunnar & Co., LLC and Feltl and Company, Inc. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants issued to purchase common stock	450,000
Additional warrants available to be issued, contractual term	45 days
Common Stock [Member] | Underwriting Agreement [Member] | Joseph Gunnar & Co., LLC and Feltl and Company, Inc. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Stock issued during period, shares, new issues	3,000,000
Shares issued, price per share (usd per share)	$ 4